India's Ranbaxy gets US okay for antihistamine tablets

April 12 (Reuters) - India's Ranbaxy Laboratories Ltd. (RANB.BO) said it got U.S. Food and Drug Administration approval to market Loratadine antihistamine tablets.

Ranbaxy's Loratadine tablets are bioequivalent to Claritin Reditabs of Schering Plough Healthcare Products, the U.S. over-the-counter and consumer products business unit of Schering-Plough Corp. SGP.N. (Reporting by Rakesh Sharma in Bangalore)